Acute Market Reports’s, ‘Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2016’, provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects.
Browse Full Report Visit - http://www.acutemarketreports.com/report/homozygous-familial-hypercholesterolemia-hofh-pipeline-review-h1-2016
Acute Market Reports’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Acute Market Reports’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Browse All Reports of This Category - http://www.acutemarketreports.com/category/healthcare-market
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Homozygous Familial Hypercholesterolemia (HoFH)
- The report reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Homozygous Familial Hypercholesterolemia (HoFH) therapeutics and enlists all their major and minor projects
- The report assesses Homozygous Familial Hypercholesterolemia (HoFH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH)
- The report reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Homozygous Familial Hypercholesterolemia (HoFH) therapeutics and enlists all their major and minor projects
- The report assesses Homozygous Familial Hypercholesterolemia (HoFH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (HoFH) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (HoFH) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Get Complete Report @ Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H1 2016
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Acute Market Reports Report Coverage 6
Homozygous Familial Hypercholesterolemia (HoFH) Overview 7
Therapeutics Development 8
Pipeline Products for Homozygous Familial Hypercholesterolemia (HoFH) - Overview 8
Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics under Development by Companies 9
Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Homozygous Familial Hypercholesterolemia (HoFH) - Products under Development by Companies 13
Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development 14
Aegerion Pharmaceuticals, Inc. 14
CymaBay Therapeutics, Inc. 15
Kastle Therapeutics LLC 16
Regeneron Pharmaceuticals, Inc. 17
RegenxBio Inc. 18
Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
AEM-28 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AEM-2802 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AEM-2814 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AM-0010 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
evinacumab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
gemcabene calcium - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lomitapide mesylate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MBX-8025 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MGL-3196 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MGL-3745 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
mipomersen sodium - Drug Profile 43
Product Description 43
Mechanism of Action 43
List of Tables 5
List of Figures 5
Introduction 6
Acute Market Reports Report Coverage 6
Homozygous Familial Hypercholesterolemia (HoFH) Overview 7
Therapeutics Development 8
Pipeline Products for Homozygous Familial Hypercholesterolemia (HoFH) - Overview 8
Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics under Development by Companies 9
Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Homozygous Familial Hypercholesterolemia (HoFH) - Products under Development by Companies 13
Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development 14
Aegerion Pharmaceuticals, Inc. 14
CymaBay Therapeutics, Inc. 15
Kastle Therapeutics LLC 16
Regeneron Pharmaceuticals, Inc. 17
RegenxBio Inc. 18
Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
AEM-28 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AEM-2802 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AEM-2814 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AM-0010 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
evinacumab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
gemcabene calcium - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lomitapide mesylate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MBX-8025 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MGL-3196 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MGL-3745 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
mipomersen sodium - Drug Profile 43
Product Description 43
Mechanism of Action 43
Latest Reports :
Hepatitis B - Pipeline Review, H1 2016
About - Acute Market Reports :
About - Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Contact Us :
Chris Paul
ACUTE MARKET REPORTS
Office No 101, 1st Floor ,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
India: +91 7755981103
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com
Contact Us :
Chris Paul
ACUTE MARKET REPORTS
Office No 101, 1st Floor ,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
India: +91 7755981103
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com
No comments:
Post a Comment